Literature DB >> 24518046

Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen.

Kyung-Wook Jo1, Jung-Wan Yoo1, Yoonki Hong2, Jae Seung Lee1, Sang-Do Lee1, Woo Sung Kim1, Dong Soon Kim1, Tae Sun Shim3.   

Abstract

BACKGROUND: We aimed to identify the 1-year relapse rate and risk factors for patients with pulmonary tuberculosis (TB) treated with a 6-month daily regimen.
METHODS: A total of 317 patients with pan-susceptible pulmonary TB who completed a 6-month daily course of treatment [2HRZ(E)/4HR(E)] were retrospectively analyzed.
RESULTS: The mean age was 50.0 ± 16.8 years and men were predominant (61.2%). All of 137 adults tested for HIV were negative. Six (1.9%) cases relapsed within one year. Relapse rate was higher in patients with a positive culture after 2 months of treatment (10.0%, p = 0.049) and in patients with both a positive culture after 2 months of treatment and cavitation on initial chest radiograph (18.2%, p = 0.015), whereas relapse rate in patients with cavitation alone was comparable to that of the total population (2.7%). Among various risk factors known to increase risk of relapse, the combined variable of cavitation and positive culture at 2 months (OR = 15.56, 95% CI 2.56-98.71, p = 0.003) was only associated with increased relapse rate in a multivariate analysis.
CONCLUSIONS: Even with a 6-month daily treatment regimen throughout the intensive and continuation phases, the relapse rate was unacceptably high in patients with both a positive culture at 2 months of treatment and cavitation on baseline chest radiography. Intensification of treatment, such as an extension of treatment duration, should be considered in this category of patients.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-Month culture conversion; Cavity; Pulmonary tuberculosis; Relapse

Mesh:

Substances:

Year:  2014        PMID: 24518046     DOI: 10.1016/j.rmed.2014.01.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment.

Authors:  Jared Eddy; Taimur Khan; Frank Schembri
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Prevalence and Impact of Diabetes Mellitus Among Patients with Active Pulmonary Tuberculosis in South Korea.

Authors:  Eun Hye Lee; Jung Mo Lee; Young Ae Kang; Ah Young Leem; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Song Yee Kim
Journal:  Lung       Date:  2017-02-09       Impact factor: 2.584

3.  A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Authors:  Laura E Via; Kathleen England; Danielle M Weiner; Daniel Schimel; Matthew D Zimmerman; Emmanuel Dayao; Ray Y Chen; Lori E Dodd; Mike Richardson; Katherine K Robbins; Ying Cai; Dima Hammoud; Peter Herscovitch; Véronique Dartois; JoAnne L Flynn; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

4.  Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.

Authors:  Bo Young Lee; Sunyoung Kim; YoonKi Hong; Sang-Do Lee; Woo Sung Kim; Dong Soon Kim; Tae Sun Shim; Kyung-Wook Jo
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 5.  Cavitary tuberculosis: the gateway of disease transmission.

Authors:  Michael E Urbanowski; Alvaro A Ordonez; Camilo A Ruiz-Bedoya; Sanjay K Jain; William R Bishai
Journal:  Lancet Infect Dis       Date:  2020-05-05       Impact factor: 25.071

6.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 7.  Treatment of Drug Susceptible Pulmonary Tuberculosis.

Authors:  Hong-Joon Shin; Yong-Soo Kwon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-06-30

Review 8.  Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.

Authors:  Cheol Kyu Park; Yong Soo Kwon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-10-31

9.  Adjunctive surgery versus medical treatment among patients with cavitary multidrug-resistant tuberculosis.

Authors:  Sergo A Vashakidze; Shota G Gogishvili; Ketino G Nikolaishvili; Zaza R Avaliani; Abivarma Chandrakumaran; Giorgi Sh Gogishvili; Mathew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Eur J Cardiothorac Surg       Date:  2021-12-01       Impact factor: 4.534

10.  Recurrent Tuberculosis Disease in Singapore.

Authors:  Suay Hong Gan; Kyi Win KhinMar; Li Wei Ang; Leo K Y Lim; Li Hwei Sng; Yee Tang Wang; Cynthia B E Chee
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.